Effect of Pyrrolobenzimidazole Derivative RU-792 on Experimental Brain Ischemia

Verfasser / Beitragende:
[V. Kosolapov, D. Sorotskii, A. Spasov, V. Anisimova]
Ort, Verlag, Jahr:
2015
Enthalten in:
Bulletin of Experimental Biology and Medicine, 159/3(2015-07-01), 372-375
Format:
Artikel (online)
ID: 605535663
LEADER caa a22 4500
001 605535663
003 CHVBK
005 20210128100848.0
007 cr unu---uuuuu
008 210128e20150701xx s 000 0 eng
024 7 0 |a 10.1007/s10517-015-2966-x  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s10517-015-2966-x 
245 0 0 |a Effect of Pyrrolobenzimidazole Derivative RU-792 on Experimental Brain Ischemia  |h [Elektronische Daten]  |c [V. Kosolapov, D. Sorotskii, A. Spasov, V. Anisimova] 
520 3 |a Compound RU-792 showed pronounced anti-ischemic activity and improved survival of rats with brain ischemia by normalizing parameters of spontaneous motor activity and reducing neurological deficit within 3 post-operative days being superior to the reference drug mexidol by this parameter. RU-792 inhibited the formation of conjugated dienes and malonic dialdehyde and increased activity of the antioxidant enzyme glutathione peroxidase thereby modulating the parameters of free radical oxidation in rats subjected to ischemia more effectively than mexidol. 
540 |a Springer Science+Business Media New York, 2015 
690 7 |a synthetic antioxidants  |2 nationallicence 
690 7 |a free radical oxidation  |2 nationallicence 
690 7 |a brain ischemia  |2 nationallicence 
700 1 |a Kosolapov  |D V.  |u Department of Pharmacology, Rostov-on-Don, Russia  |4 aut 
700 1 |a Sorotskii  |D D.  |u Laboratory of Pharmacology of Antioxidant Substances, Research Institute of Pharmacology, Volgograd State Medical Academy, Rostov-on-Don, Russia  |4 aut 
700 1 |a Spasov  |D A.  |u Department of Pharmacology, Rostov-on-Don, Russia  |4 aut 
700 1 |a Anisimova  |D V.  |u Research Institute of Physical and Organic Chemistry, Southern Federal University, Rostov-on-Don, Russia  |4 aut 
773 0 |t Bulletin of Experimental Biology and Medicine  |d Springer US; http://www.springer-ny.com  |g 159/3(2015-07-01), 372-375  |x 0007-4888  |q 159:3<372  |1 2015  |2 159  |o 10517 
856 4 0 |u https://doi.org/10.1007/s10517-015-2966-x  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s10517-015-2966-x  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Kosolapov  |D V.  |u Department of Pharmacology, Rostov-on-Don, Russia  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Sorotskii  |D D.  |u Laboratory of Pharmacology of Antioxidant Substances, Research Institute of Pharmacology, Volgograd State Medical Academy, Rostov-on-Don, Russia  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Spasov  |D A.  |u Department of Pharmacology, Rostov-on-Don, Russia  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Anisimova  |D V.  |u Research Institute of Physical and Organic Chemistry, Southern Federal University, Rostov-on-Don, Russia  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t Bulletin of Experimental Biology and Medicine  |d Springer US; http://www.springer-ny.com  |g 159/3(2015-07-01), 372-375  |x 0007-4888  |q 159:3<372  |1 2015  |2 159  |o 10517